Lancet publication of the Oxford AstraZeneca phase 3 COVID-19 vaccine trial

We recently heard the interim high-level results from phase 3 clinical trials of the Oxford AstraZeneca COVID-19 vaccine in the UK and Brazil.

The scientists have now published the results in the Lancet.

Journalists dialled in to this briefing to hear from the scientists involved and ask them their questions.

Speakers included:

Prof Andrew Pollard, Director of the Oxford Vaccine Group, Department of Paediatrics, University of Oxford

Prof Sarah Gilbert, Saïd Professorship of Vaccinology, Jenner Institute, Nuffield Department of Medicine, University of Oxford

Pascal Soriot, Chief Executive Officer, AstraZeneca

Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D, AstraZeneca

This Briefing was accompanied by an SMC Roundup of Comments.

in this section